Low dose fenoterol aerosol protects against histamine-induced bronchoconstriction in mild asthmatics: a dose response study.
Sixteen subjects with mild stable asthma participated in a randomized double blind study on the effects of low dose fenoterol against histamine induced bronchoconstriction. Fenoterol aerosol at concentrations of 10, 50 and 200 micrograms and placebo were delivered at random through a metered dose inhaler as a single dose 30 min before histamine challenges on four separate occasions. Compared to placebo a fenoterol dose of 10 micrograms provided significant bronchodilatation (sRaw [s.d.] 8.3 [2.73] vs 6.3 [1.74] cm H2O* s [P less than 0.05]) and protection (PC100 sRaw [s.e.m.] 0.72 (1.31) vs 1.45 (1.39) mg/ml). The bronchodilatory and protective actions of fenoterol were more pronounced after the inhalation of 200 micrograms (P less than 0.05) with no difference between 10 and 50 micrograms fenoterol aerosol. The magnitude of bronchodilatation and protection was not correlated (r = 0.15). The results from this acute study may suggest that fenoterol at doses up to 20 times lower than routinely recommended may be an effective treatment in mild asthmatics.
Magnussen
H
H
Krankenhaus Grosshansdorf, Zentrum für Pneumologie und Thoraxchirurgie, Germany.
Rabe
K F
KF
D000328:Adult; D000336:Aerosols / Q000008:administration & dosage / Q000627:therapeutic use; D001249:Asthma / Q000503:physiopathology / Q000517:prevention & control*; D016535:Bronchial Hyperreactivity / Q000503:physiopathology / Q000517:prevention & control*; D016084:Bronchoconstriction / Q000187:drug effects; D004304:Dosage Forms; D004305:Dose-Response Relationship, Drug; D004311:Double-Blind Method; D005260:Female; D005280:Fenoterol / Q000008:administration & dosage* / Q000627:therapeutic use; D006632:Histamine; D006801:Humans; D008297:Male; D010919:Placebos; D012129:Respiratory Function Tests
D000336:Aerosols; D004304:Dosage Forms; D010919:Placebos; D005280:Fenoterol; D006632:Histamine